Biopharmaceuticals
Neurology
News Release - June 3, 2021
vasopharm GmbH Announces Results of the NOSTRA III Traumatic Brain Injury Phase III Study
Source: vasopharm
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.